WhatistheSymbol
Elan Corp Plc -spons Adr trades in the stock market under the ticker symbol of ELN. Search for the ticker of any public company above using the 'Get Ticker' search in red.

Who is Elan Corp Plc -spons Adr?

Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It engages in the research, development, and commercial activities primarily in the areas of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), and Crohn’s disease. The company offers Tysabri to treat relapsing forms of MS. This segment also develops ELND005, a beta amyloid anti-aggregation agent to treat Alzheimer’s disease; beta amyloid immunotherapies for the treatment of Alzheimer’s disease through its collaboration with Wyeth; and gamma secretase inhibitors and Beta secretase inhibitors for Alzheimer’s disease, as well as develops ELND002, a novel alpha4 integrin inhibitor for the treatment of MS, which is in Phase Ib/IIa clinical trials. In addition, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn’s disease, as well as focuses on developing novel antibodies based on neo-epitope targets for treatment of Alzheimer’s disease, Parkinson’s disease, AL amyloidosis, and diabetes. The company was founded in 1969 and is headquartered in Dublin, Ireland.

www.elan.com
412 Employees
Last Reported Date: 02/23/12
Founded in 1969
Last $10.89 USD
Change Today +0.05 / 0.46%
Volume 3.0M
As of 4:15 PM 10/25/12 All times are local (Market data is delayed by at least 15 minutes).

elan corp plc -spons adr (ELN) Snapshot

Open
$10.85
Previous Close
$10.84
Day High
$11.04
Day Low
$10.76
52 Week High
03/21/12 - $15.27
52 Week Low
11/25/11 - $9.82
Market Cap
6.5B
Average Volume 10 Days
5.2M
EPS TTM
$-0.49
Shares Outstanding
593.5M
ELN Does Not Pay Dividends
P/E TM
--
ELN:US Historical Stock Quote
ELN:US Advanced Stock Chart

Related News

No related news articles were found.

elan corp plc -spons adr (ELN) Related News

Briefs

elan corp plc -spons adr (ELN) Key Developments

Elan Corporation, plc Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012; Re-Affirms Earnings Guidance for the Full Year 2012; Reports Impairment Charge for the Third Quarter Ended September 30, 2012

Elan Corporation, plc reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2012. For the quarter, the company’s total revenue increased by 10% to $306.6 million from $279.4 million for the same period of 2011. Operating loss was $56.2 million against operating income of $37.8 million a year ago. Net loss from continuing operations before tax was $217.0 million against $3.0 million a year ago. Net loss from continuing operations was $216.2 million or $0.36 diluted per share compared to net income from continuing operations of $3.5 million or $0.01 diluted per share for the third quarter of 2011. Net loss was $229.9 million against net income of $674.1 million a year ago. LBITDA was $196.1 million against EBITDA of $32.4 million a year ago. Adjusted EBITDA increased by 38% to $67.6 million from $49.1 million for the same period of 2011, principally reflecting the 13% increase in patients taking Tysabri, and a 9% decrease in operating expenses, partially offset by the revenue reserve for Italy and unfavorable foreign currency movements. Cash flows provided by operating activities were $15.9 million against $103.3 million a year ago. Net purchases of tangible and intangible assets were $3.8 million against $10.0 million a year ago. For the nine months, the company’s total revenue increased by 11% to $883.0 million from $797.1 million for the same period of 2011, as a result of a 6% growth in global in-market net sales of Tysabri to $1,198.3 million for the nine months ended September 30, 2012, from $1,131.0 million for the same period of 2011. Operating income was $0.4 million against $88.7 million a year ago. Net loss from continuing operations before tax was $260.1 million against $60.9 million a year ago. Net loss from continuing operations was $260.0 million or $0.44 diluted per share against $60.0 million or $0.10 diluted per share for the third quarter of 2011. Net loss was $290.2 million against net income of $695.2 million a year ago. LBITDA was $197.2 million against EBITDA of $48.0 million a year ago. Adjusted EBITDA increased by 22% to $160.0 million from $131.1 million for the same period of 2011, principally reflecting the continued growth of Tysabri. Cash flows provided by operating activities of $29.0 million against cash flows used in operating activities of $6.2 million a year ago. Net purchases of tangible and intangible assets were $9.8 million against $21.1 million a year ago. The company re-affirmed earnings guidance for the full year 2012. For the year, the company re-affirms that it expects to generate full-year 2012 adjusted EBITDA of greater than $200 million. This also reflects the company’s expectation that the Tysabri Italian price dispute is unlikely to be resolved this year, as well as the re-classification of Neotope to discontinued operations. The company expects full-year 2012 revenues of approximately $1.2 billion. The company reported impairment charge for the third quarter ended September 30, 2012. For the quarter, the company reported impairment charge of $117.3 million related to the Janssen AI equity method investment following the announcement by Johnson & Johnson of the discontinuation of the development of bapineuzumab intravenous in mild to moderate Alzheimer’s disease during the third quarter of 2012.

Elan Mulls Acquisitions

Elan Corporation, plc is seeking acquisitions. Elan, said it is looking at acquisitions, although it declined to say what size it had in mind.

Biogen Idec Inc. and Elan Corporation, plc announced Results from 11 Company-Sponsored Tysabri Presentations

Biogen Idec Inc. and Elan Corporation, plc announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28(TH) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 -- 13. Key data highlights from ECTRIMS include: Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI Observational Program (TOP) -- Poster 519; Improvement of MS-related fatigue also significantly improves quality of life in patients treated with natalizumab: results from the TYNERGY trial -- Poster 445; Relation of disease activity-free status to visual function in the AFFIRM trial -- Poster 557; Utilization of JC-virus antibody testing in clinical practice -- Poster 546; Imaging findings for PML in natalizumab-treated MS patients -- Platform 99.

Most Popular on

The Five Scariest Airports to Land a Plane
Why Women Earn Less Than Men a Year Out of School
Apple’s Slim iMac Far Outshines the New iPad Mini
The Surprises in the $1 Billion Bank Suit
Convincing Women in China They're Too Hairy
More News
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELN:US $10.89 USD +0.05

ELN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo Health Solutions Inc $29.70 USD +0.08
Ipsen SA €18.44 EUR +0.135
Medicis Pharmaceutical Corp $43.32 USD +0.02
Ranbaxy Laboratories Ltd 532.10 INR -8.50
Virbac SA €136.75 EUR -0.15
 

Industry Analysis

ELN

Industry Average

Valuation ELN Industry Range
Price/Earnings 11.8x
Price/Sales 5.0x
Price/Book 8.1x
Price/Cash Flow 14.2x
TEV/Sales 4.0x
 | 

Post a JobJobs


    We are currently experiencing technical difficulties. Please try again later.
Simply Hired

Sponsored Links

Another SAC Down, One To Go, Or Will It Be Two? Wake Up Martoma

[at Forbes] - The time has come for Mathew Martoma to plead guilty and testify against SAC's Steven Cohen. It may be his only chance after today's conviction of SAC's Michael Steinberg.

18 Dec 2014

Read More...
Perrigo Company plc Completes Acquisition of Elan Corporation, plc

[Business Wire] - Perrigo Company plc and Elan Corporation, plc today announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion.

18 Dec 2014

Read More...
New catalyst for ol' Jim Cramer fave?

[at CNBC] - Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts to drive shares higher.

16 Dec 2014

Read More...
Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigo's Proposed Acquisition Of Elan

[at noodls] - Dec 13, 2013 ALLEGAN, Mich.and DUBLIN, Dec. 13, 2013/PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) and Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that the Irish High Court ...

13 Dec 2014

Read More...
Perrigo Company and Elan Corporation Plc Receive Irish High Court Approval for Perrigo’s Proposed Acquisition of Elan

[at noodls] - Perrigo Company and Elan Corporation Plc Receive Irish High Court Approval for Perrigo's Proposed Acquisition of Elan ALLEGAN, Mich. & DUBLIN--(BUSINESS WIRE)--Dec. 13, 2013-- Perrigo Company (NYSE:PRGO; ...

13 Dec 2014

Read More...
Elan, Perrigo receive Irish approval for acquisition

[theflyonthewall.com] - Perrigo (PRGO) and Elan (ELN) announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan. The acquisition of Elan will be effected by a “scheme of arrangement” under Irish law ...

13 Dec 2014

Read More...
Perrigo, Elan receive Irish High Court approval for acquisition

[theflyonthewall.com] - Perrigo and Elan had entered into a transaction agreement pursuant to which Perrigo agreed to acquire Elan through the formation of a new Irish holding company that has since been renamed Perrigo Company. ...

13 Dec 2014

Read More...
Elan Corporation, plc

[Zacks] - Elan Corporation, plc (ELN) is Overbought, What's Next?

5 Dec 2014

Read More...
Asian markets start nervous, set for tense day amid Fed angst

4 Dec 2014

Read More...
Hedge fund 'VIP' list

[at CNBC] - CNBC's Scott Wapner highlights popular longs that investors will find in the portfolios of top hedge fund managers. The "Fast Money" traders weigh in.

27 Nov 2014

Read More...
  • 1
  • 0
  • 0

Get our Stock Market & Financial Investment news alerts in your inbox

Read our full disclaimer and privacy policy